P. Johnston
Sanofi S.A.
3 Papers
P. Johnston is an academic researcher from Sanofi S.A.. The author has contributed to research in topics: Type 2 diabetes & NPH insulin. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Reply to Chantelau E [letter] and Currie CJ [letter]
Julio Rosenstock,Vivian Fonseca,Janet B. McGill,Matthew C. Riddle,J.-P. Hallé,Irene Hramiak,P. Johnston,M. Davis +7 more
TL;DR: The selection of the patient population and the exclusion of established proliferative DR in the study, comments on the protective effects of metformin against cancer, proposes multiple arbitrary post hoc subgroup analyses, and notes that insulin glargine and NPH insulin resulted in similar glycaemic control are questioned.
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.
Julio Rosenstock,Vivian Fonseca,Janet B. McGill,Matthew C. Riddle,J.-P. Hallé,Irene Hramiak,P. Johnston,M. Davis +7 more
TL;DR: Although the study was not designed to investigate the frequency of tumour development, the long duration of the trial enables a comparative assessment of the occurrence of benign or malignant tumours with insulin glargine and NPH insulin during more than 4 years of exposure, captured as adverse events in the course of routine safety monitoring.
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
Julio Rosenstock,Vivian Fonseca,Janet B. McGill,Matthew C. Riddle,J.-P. Hallé,Irene Hramiak,P. Johnston,M. Davis +7 more
TL;DR: This study shows no evidence of a greater risk of the development or progression of diabetic retinopathy with insulin glargine vs NPH insulin treatment in patients with type 2 diabetes mellitus.